Nerandomilast
Medication
From Wikipedia, the free encyclopedia
Nerandomilast, sold under the brand name Jascayd, is a medication used for the treatment of idiopathic pulmonary fibrosis and progressive pulmonary fibrosis.[1] It is a phosphodiesterase 4 (PDE4) inhibitor.[1][4] It is taken by mouth.[1]
| |
| Clinical data | |
|---|---|
| Trade names | Jascayd |
| Other names | BI-1015550, BI 1015550 |
| AHFS/Drugs.com | Multum Consumer Information |
| MedlinePlus | a625107 |
| License data | |
| Drug class | Phosphodiesterase-4 inhibitor |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C20H25ClN6O2S |
| Molar mass | 448.97 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Side effects include diarrhea, decreased weight, decreased appetite, and nausea.[5]
Nerandomilast was approved for medical use in the United States in October 2025.[6]
Medical uses
Nerandomilast is indicated for the treatment of idiopathic pulmonary fibrosis and for the treatment of progressive pulmonary fibrosis.[1][5][7]
Idiopathic pulmonary fibrosis affects the tissue surrounding the air sacs, or alveoli, in the lungs.[6] It develops when this lung tissue becomes thick and stiff.[6] Over time, these changes can cause permanent lung scarring (fibrosis) that makes it more difficult to breathe.[6]
Progressive pulmonary fibrosis is a chronic disease characterized by gradual, irreversible scarring of the lungs, which can lead to progressive breathing difficulties.[5] Progressive pulmonary fibrosis is an umbrella term that can describe progressive lung scarring in many interstitial lung diseases.[5]
Side effects
Side effects include diarrhea, decreased weight, decreased appetite, and nausea.[5]
History
The efficacy of nerandomilast for the treatment of idiopathic pulmonary fibrosis was evaluated in two randomized, double-blind, placebo-controlled trials of adults with idiopathic pulmonary fibrosis.[6]
The efficacy of nerandomilast for the treatment of progressive pulmonary fibrosis was demonstrated in FIBRONEER-ILD (NCT05321082), a randomized, double-blind, placebo-controlled study that enrolled 1,178 adults with progressive pulmonary fibrosis.[5] Participants were randomly assigned 1:1:1 to receive twice daily administration of nerandomilast 9 mg, nerandomilast 18 mg, or placebo, for at least 52 weeks.[5]
Society and culture
Legal status
Nerandomilast was approved for medical use in the United States in October 2025.[8][9]
The US Food and Drug Administration granted the application for nerandomilast an orphan drug designation for the idiopathic pulmonary fibrosis indication[10] and breakthrough therapy designation for the progressive pulmonary fibrosis indication.[5]
Names
Nerandomilast is the international nonproprietary name.[11]
Nerandomilast is sold under the brand name Jascayd.[1]
